Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Patient experience & cancer outcomes researcher | Leukemia & palliative care doc | Chief PX and Safety Officer

@DukeCancer

| HeForShe. Tweets mine.

Durham, NCmedicine.duke.edu/faculty/thomas…Joined March 2012

1,483 Following

4,665 Followers

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO’s Tweets

Pinned Tweet

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Sep 19, 2019

I’m on #CapitolHill today discussing #palliative care, specifically the fact that blood #cancer patients are being put in a terrible position at end of life: being forced to choose between hospice and receiving #palliative blood transfusions #hpm #hapc (1/14)

240

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Tatiana Prowell, MD

@tmprowell

Jan 15

If you notice blood in your stool or a persistent change in your bowel habits, see a dr. We don’t understand why we are seeing so much more colorectal cancer in younger adults. Start colon cancer screening at age 45 or earlier if at increased risk: cdc.gov/cancer/colorec #crcsm

Quote Tweet

Ibrahim Halil SAHIN, MD

@IbrahimSahinMD1

Jan 15

Colorectal cancer is now the leading cause of cancer related death among males aged 20-39 and 40-49

It was third among 20-39 age group last year.

Concerning trend is also seen in young women; CRC related death and will likely surpass breast cancer in near future @OncoAlert

Show this thread

102

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Opinion Health

@OpinionHealth

Jan 10

Opinion Health are looking for those diagnosed with AML (Acute Myeloid Leukemia) or their caregivers for a 60 minutes online interview in the US. Please click to register your interest.

opinionhealth.co.uk

AML Research Interview

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

🔔

: How do war metaphors impact patients living with cancer? ✅Promote positivity, situate diagnosis within larger life story vs. ❎Unhelpful b/c assume lack of control over outcome Read more, 🧵 below:

pubmed.ncbi.nlm.nih.gov

"More than conquerors": a qualitative analysis of war metaphors for patients with cancer - PubMed

The war metaphor should remain an integral part of cancer care. Disregarding war metaphors robs patients of an important framework for meaning-making-one that may promote strength, continuity, and...

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Nida Qadir, MD

@NidaQadirMD

Jan 8

The prayers for #DamarHamlin are beautiful, but

@NFL

, please also consider spending 2 minutes before tomorrow’s games showing a demo of hands-only #CPR & encouraging viewers to learn. With your audience, this could save lives ❤️🙏🏽 Read on to learn how to do hands-only CPR ⬇️

501

2,823

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Brave Enough MD

@RUBraveEnough

Jan 6

How you can support women who speak up: 1️⃣Amplify what they said 2️⃣Thank them publicly 3️⃣Protect their reputation in spaces they’re not in 4️⃣Defend them by giving them a platform to speak Women who🗣️up for equity pay a price. How will you support them?

@womenMDinanesth

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Lexie Mannix, MD

@ALMannixMD

Jan 3

Seeing how much the world accepts that it’s impossible to move on after watching CPR really makes me think about how we (medical professionals, especially those who work in Emergency departments) are expected to just move on immediately after a code.

656

6,990

52.4K

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD

@LeukDocJZ

Dec 23, 2022

Excited to share our new paper in

@Haematologica

- Time Without Transfusion Reliance (TWiTR)- a new assessment tool for eval. of new Tx's in MDS. Credit to

@MikkaelSekeres

for coming up with catchy acronym (MASTODON did not seem to fit 😀). haematologica.org/article/view/h

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Talha Badar

@TalhaBadarMD

Dec 13, 2022

#ASH22 #leusm Kudos!!! to Dr. Litzow

@MRLitzow

and

@eaonc

team for this randomized study and practice changing!! It is not easy… The study reach primary endpoint for OS advantage!! 👏🏽👏🏽👏🏽

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD

@LeukDocJZ

Dec 12, 2022

Interesting data from Munich showing that TP53 mut MDS/AML is not 1 disease. Majority are multi-hit mut if >5% blasts. Outcomes significantly worse for multi-hit TP53 mut MDS or AML. #ASH22

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD

@LeukDocJZ

Dec 12, 2022

Still early data with triplets in #AML but great & compelling presentation by

@NicholasShortMD

on Aza/Ven/Gilteritinib in both newly Dx & R/R FLT3 mut AML. All newly Dx pts responded and most by D14. Early de-escalation strategies will be critical for triplets in #AML. #ASH22

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Talha Badar

@TalhaBadarMD

Dec 12, 2022

#ASH22 #leusm Q: Are non chemotherapy options are better than chemotherapy for Ph+ve ALL? Phase II data is excellent with dasatinib + Blin and ponatinib + Blin. Eagerly waiting for Phase III 👇🏽 trial results!

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Toby Eyre

@tobyeyre82

Dec 12, 2022

#pirtobrutinib #CLL BRUIN trial data further improving over time ORR >80% in 247 heavily R/R #CLL in post cBTKi setting #ASH22

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

David Steensma, MD

@DavidSteensma

Dec 13, 2022

It would be great to have a therapy to reduce the harmful events associated with CHIP. Unfortunately aspirin doesn't seem to be the answer - Zoe McQuilten

@MonashUni

presented genetic analysis from the ASPREE RCT. Peculiarly, no CHIP/CV association (event rates were low).#ASH22

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD

@LeukDocJZ

Dec 12, 2022

Disappointed to see the data from STIMULUS-MDS1 presented by the one and only

@Dr_AmerZeidan

. Sabatolimab/HMA not significantly > HMA alone in HR-MDS. Interested in correlates & predictors of response/durability. Eagerly awaiting RP3 data of HMA combos in #MDS. #ASH22

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD

@LeukDocJZ

Dec 13, 2022

An honor to present our ‘Trial in Progress’ on behalf of the Beat AML consortium. Phase 1b study of Aza/Ven/SNDX-5613 (menin inhibitor) in newly Dx older/unfit #AML with MLL or NPM1 mut. High unmet need that we hope a triplet can make a huge impact #ASH22

@UNC_Lineberger

@LLSusa

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Congress | #ASH22

gives a thought-provoking presentation on transplantation in pts with TP53-mutated MDS and AML. While outcomes are poor, allo-HSCT is associated with improved survival compared to not transplanting in pts with MDS. #leusm

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

calliecoombs

@calliecoombsmd

Dec 13, 2022

Huge CHIP study that showed no association for CHIP and CVD (though did show an association for CHIP and cancer, including non-hematologic). Detriment to OS when VAF>10%. No benefit to aspirin. #ASH22

117

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Dec 12, 2022

Triplets in #AML! Early phase results with aza + #venetoclax + #gilteritinib in FLT3m disease: 100% response rate in newly dx cohort! (95% CR, rest MLFS). Lots of myelosuppression, and early responses requiring stopping ven/gilt at d14 marrow ash.confex.com/ash/2022/webpr #ASH22 #leusm

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD

@LeukDocJZ

Dec 10, 2022

Very impressive data with oral Menin inhibitors in R/R AML w/ MLL or NPM1 mut presented by

@GhayasIssa

& Harry Erba. This mechanism certainly looks like the most promising new wave of ‘targeted Tx’ for AML. Interested in seeing combination strategies w/ these agents. #ASH22

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD

@LeukDocJZ

Dec 10, 2022

Another fantastic presentation by

@Daver_Leukemia

reporting on Aza/Ven/Magrolimab in #AML. In the 1L setting, regimen looks promising w/impressive data in TP53 mut. The question is whether Ven adds anything or is it all the Magro in TP53mut? ENHANCE-2/3 enrolling! #ASH22

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD

@LeukDocJZ

Dec 11, 2022

Long term F/U data on Aza/Ven as 1L Tx from VIALE-A 👇. Great talk by

@PratzKW

. Impressed by the durability of CR. Although Aza/Ven is a true game changer, we need to be humbled that few if any are cured & long-term OS is still poor. This is a foundation to build on! #ASH22

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Dec 11, 2022

Proud of two superstar

@dukemedicine

trainees Drs. Allison Taylor and Chris Wanjiku, delivering oral presentations on their research tonight at #ASH22. Go Duke! Kudos to

@ASH_hematology

for investing in these rising stars in Hematology!

@DukeIMChiefs

@DukeCancer

@DukeHealth

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Dec 9, 2022

Lots of hot #AML data at #ASH22! I'm particularly interested in abstracts on #menin inhibitors, #lintuzumab RIT, HEOR/RWE #venetoclax studies, long-term outcomes updates (e.g. VIALE-A) as well as novel combinations/approaches (e.g. 7+7d aza/ven regimen, ven/gilt) #leusm

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Dec 9, 2022

Data on all-oral #venetoclax and #gilteritinib regimen in R/R #AML just published, and in #ASH22. High ORR, 75% mCRc, but 36% MLFS and just 18% CR. Very myelosuppressive but effective. Good bridge to alloHSCT in R/R FLT3m AML? #leusm ascopubs.org/doi/full/10.12

@Daver_Leukemia

ascopubs.org

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut...

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Dec 9, 2022

Who at #ASH22 is ready to take the next step in their career, to lead our vibrant Division of Hematologic Malignancies and Cellular Therapy

@DukeCancer

? We're still seeking applicants; link below. Feel free to contact me if interested. medicine.duke.edu/news/seeking-c #leusm #lymsm #mmsm

medicine.duke.edu

Seeking Candidates for Chief of the Division of Hematologic Malignancies & Cellular Therapy

Deadline to apply is Dec. 1, 2022

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Nathan A. Pennell MD, PhD, FASCO

@n8pennell

Nov 23, 2022

Prior authorization is harming individuals with cancer according to new survey results from

@ASCO

old-prod.asco.org/news-initiativ WITH RECOMMENDATIONS to #fixpriorauth!

THREAD 1/15

Nearly All Oncology Providers Report Prior Authorization Causing

Prior authorization is harming individuals with cancer according to new survey results from the Association for Clinical Oncology (ASCO). The survey found that prior authorization delays necessary

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Elizabeth Jacobs, PhD

@TheAngryEpi

Nov 6, 2022

It’s weird how many people in public health have forgotten how deeply unpopular helmet, seatbelt, and smoking laws once were. Our job in public health isn’t to win popularity contests. It’s to study how to best protect the health of the public, and then enact the things that work

432

12.1K

50.6K

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Introvert Problems

@IntrovertProbss

Nov 5, 2022

People always tell introverts to be more talkative and leave their comfort zones, yet no one tells extroverts to shut up and make the zone comfortable

231

5,546

29.9K

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Joshua Zeidner MD

@LeukDocJZ

Oct 31, 2022

Grab some tissues and watch this! Such an incredibly moving and inspiring story. THIS is why we do what we do! 🙏

Quote Tweet

CBS Sunday Morning

@CBSSunday

Oct 30, 2022

Emily Whitehead became the first child to receive genetically-modified T cell to treat her leukemia. Her story helped launch @EWhiteheadFdn and the field of cellular medicine, as told in a new book, #TheSongoftheCell by the Pulitzer Prize-winning, @DrSidMukherjee.

6:24

91.3K views

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Oct 29, 2022

Come join our team! - Duke Health Seeks Hematologic Malignancies Specialist #leusm

@DukeCancer

@DukeHMCT

careercenter.asco.org

Duke Health Seeks Hematologic Malignancies Specialist - Durham, North Carolina (US)

The Division of Hematologic Malignancies & Cellular Therapy in the Department of Medicine and the Duke Cancer Institute is actively recruiting for…

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

ASH

@ASH_hematology

Oct 26, 2022

Four new members have been elected to the ASH Executive Committee 🌟 We're eager to see what's in store under their leadership! Learn more: loom.ly/QaOloU8

0:18

973 views

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Ramy Sedhom, MD

@ramsedhom

Oct 24, 2022

Thank you to all of the trailblazers in #pallonc who made a situation like this even possible 35+ people together on

@ASCO

communities of practice call on how to integrate a career in onc & pall care Excited to see the future move oncology care forward!

Eduardo Bruera MD and 6 others

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Adam Grant

@AdamMGrant

Oct 18, 2022

Confirmation bias is twisting the facts to fit your beliefs. Critical thinking is bending your beliefs to fit the facts. Seeking the truth is not about validating the story in your head. It's about rigorously vetting and accepting the story that matches the reality in the world.

104

2,450

7,785

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Amer Zeidan MBBS,MHS ‏عامر زيدان

@Dr_AmerZeidan

Oct 19, 2022

@Ramikomrokji

showing why we need to do better in TP53 mutated #AMLsm and #MDSm despite use of alloBMT

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

ASCO

@ASCO

Oct 15, 2022

Learn about how electronic patient reported outcomes, mobile apps & wearable technologies are changing how we deliver oncology care ➡️ fal.cn/3sLeG

@hannahdzmd

@tomleblancMD

#ASCOEdBook #healthtech

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Oct 4, 2022

Great podcast on careers in #hematology and #medicine, and #mentorship, with

and

from

, in honor of Hispanic Heritage Month, here: podcasts.apple.com/us/podcast/ash #LatinxHeritageMonth

@DukeCancer

(go Joanna!!)

podcasts.apple.com

‎The Hematologist: ASH Celebrates Hispanic Heritage Month, With Drs. Ruben Mesa, Diego Adrianzen-...

‎Show The Hematologist, Ep ASH Celebrates Hispanic Heritage Month, With Drs. Ruben Mesa, Diego Adrianzen-Herrera, & Joanna Robles, Introduced by Dr. Belinda Avalos - Sep 22, 2022

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Communities of Practice meeting for the PALLIATIVE CARE group will be: Mon, Oct 24th@ 3:00pmET Topic: Career Trajectories for dual-trained clinicians Featuring: 🌟

Toby Campbell, Pallavi Kumar & more!

Show this thread

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO Retweeted

Adam Grant

@AdamMGrant

Sep 29, 2022

Bad leaders see power as an opportunity. Good leaders see it as a responsibility. Framing power as a responsibility can discourage leaders from being selfish, making risky decisions, and ignoring advice. It's time to teach people that power is for service, not self-interest.

1,414

4,369

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Sep 29, 2022

Proud to be participating in a

@DukeHealth

#patientexperience retreat today, representing our team

@DukeCancer

. Reminded how important it is to recognize our amazing team members and their efforts. "What is recognized gets repeated" - thanks for reminding us

@ChrissyDanielsU

! #PX